Investors who were paying attention to this “slow” session after July 4th were in a buying mood on Thursday. The major indices more than made up for Tuesday’s late-day selloff even as world economies brace for tariffs tomorrow. Micron rebounded a bit after getting shellacked on Tuesday when China temporarily banned the company’s chips from being sold in the country. As a result, a strong performance in tech boosted the NASDAQ by 1.12% to 7586.4. Meanwhile, the S&P gained 0.86% to 2736.6 and the Dow rose 0.75% to 24,356.7. All of the major indices now head into an eventful Friday session with gains for the week. “Today didn’t feel overwhelmingly bullish, but it was nice to get most of the Tuesday drop back. I really don’t know what will happen tomorrow and over the weekend, but the market doesn’t seem that scared,” said Jeremy in Counterstrike. The plan for a lot of investors was to extend the holiday and pretty much take Thursday and Friday off. But while volume could be slow to end the week, there won't be any break in the headlines. The U.S. is all set to impose $34 billion worth of tariffs on Chinese imports starting tomorrow, and Beijing stands ready to retaliate immediately. The market, though, was unfazed by the deadline, perhaps taking some solace from a possible thaw in tensions between the U.S. and European car makers. Another potentially huge event scheduled for Friday is the Government Employment Situation report. Last month, the economy added 223,000 jobs, which beat expectations of about 190,000 while the unemployment rate fell to 3.8%. This morning’s ADP report was slightly less than expected with 177,000 jobs being added last month, though this number is not exactly a bellwether for the BLS. On Thursday, Healthcare Innovators cashed in a double-digit winner and replaced it with an old favorite that just keeps moving higher. Counterstrike also went to the bank and secured a double-digit profit in response to the drop in oil prices. Finally, Stocks Under $10 used this low volume session to add two smaller-than-normal picks. Learn all about it below: Today's Portfolio Highlights: Healthcare Innovators: Small caps are often “lonely” plays since they have such scant analyst coverage. So even though heart instrument maker AngioDynamics (ANGO) has been a winner for the portfolio since its inception in May 2017, Kevin would rather focus on top ideas that offer more research for their rallies. Therefore, he sold ANGO on Thursday for a 43.6% return and picked up a new/old name. In May, the editor sold Align Technology (ALGN) for a nearly 150% profit. Since then, this maker of Invisalign “smile straighteners” continued to enjoy rising earnings estimates and price targets. So the recent pullback to under $340 was a great opportunity to get back into this long-term play. Kevin added the name again today and would pick up even more on a pullback, as he expects this stock to move back above $370 in short order. Read the full write-up for a lot more on these moves. Counterstrike: With crude oil down more than 1% on Thursday morning, Jeremy felt it was a good time to cash in the portfolio’s VelocityShares 3X Long Crude Oil ETN (UWT) position just short of his targets. This is a volatile name that can swing by 10% on a whim, so the editor wasted no time and cashed in a nice 39.4% return in exactly one month. Stocks Under $10: With volume expected to be light in these two days after the Fourth of July holiday, Brian Bolan saw an opportunity to add a couple of smaller-than-normal names to the portfolio. The editor picked up Akoustis Technologies (AKTS), an approximately $170 million company that has radio frequency technology that could be a game changer. He also bought IEC Electronics (IEC), a $60 million electronics parts maker and tester that reported a huge bottom line beat in its most recent quarter. Word of caution: Brian does not want you to chase these small names if they move significantly higher. Read his full write-up for specifics on both of these new buys. All the Best, Jim Giaquinto Recommendations from Zacks' Private Portfolios: Believe it or not, this article is not available on the Zacks.com website. The commentary is a partial overview of the daily activity from Zacks' private recommendation services. If you would like to follow our Buy and Sell signals in real time, we've made a special arrangement for readers of this website. Starting today you can see all the recommendations from all of Zacks' portfolios absolutely free for 7 days. Our services cover everything from value stocks and momentum trades to insider buying and positive earnings surprises (which we've predicted with an astonishing 80%+ accuracy). Click here to "test drive" Zacks Ultimate for FREE >> Zacks Investment Research